Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.

Expert review of anticancer therapy - 1 Aug 2011

Cibula David, Zikan Michal, Dusek Ladislav, Majek Ondrej

Abstract excerpt

Prophylactic salpingo-oophorectomy is currently the only effective strategy available for decreasing ovarian cancer risk in BRCA1/2 mutation carriers. Significantly decreased risk of ovarian cancer associated with the use of combined oral contraceptives (COCs) was shown in the general population, which could be an alternative approach for those who do not accept risk-reducing surgery. Cohort, case-control and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Contraceptives, Oral

Share to Heterozygote

Share to Ovarian Neoplasms

Share to Risk Factors

Source

Identifiers

PMID: 21916573
DOI: 10.1586/era.11.38

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.PMID 21916573Read ↗

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.Semantic proximity Read ↗

Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.Semantic proximity Read ↗

Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.Semantic proximity Read ↗

Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.Semantic proximity Read ↗

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.Semantic proximity Read ↗

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.Semantic proximity Read ↗

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.Semantic proximity Read ↗

Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.Semantic proximity Read ↗

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.Semantic proximity Read ↗

Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.